Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$0.41 USD
-0.01 (-3.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.41 0.00 (1.11%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Bionano Genomics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 102 | 113 | 251 | 38 | 17 |
Receivables | 9 | 7 | 5 | 3 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 23 | 30 | 12 | 3 | 3 |
Other Current Assets | 6 | 7 | 4 | 2 | 1 |
Total Current Assets | 140 | 157 | 272 | 47 | 28 |
Net Property & Equipment | 23 | 18 | 10 | 5 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 34 | 118 | 83 | 9 | 0 |
Deposits & Other Assets | 8 | 3 | 1 | 0 | 0 |
Total Assets | 214 | 308 | 377 | 60 | 30 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 70 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 13 | 10 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 20 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 11 | 10 | 6 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 10 | 1 | 0 | 0 |
Total Current Liabilities | 100 | 36 | 22 | 9 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 16 | 0 |
Non-Current Capital Leases | 4 | 4 | 4 | 0 | 0 |
Other Non-Current Liabilities | 11 | 13 | 9 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 118 | 58 | 40 | 25 | 27 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 677 | 599 | 554 | 179 | 106 |
Retained Earnings | -581 | -349 | -216 | -144 | -103 |
Other Equity | 0 | -1 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 96 | 249 | 337 | 35 | 4 |
Total Liabilities & Shareholder's Equity | 214 | 308 | 377 | 60 | 30 |
Total Common Equity | 96 | 249 | 337 | 35 | 4 |
Shares Outstanding | 45.70 | 29.60 | 28.90 | 19.00 | 3.40 |
Book Value Per Share | 2.10 | 8.43 | 11.67 | 1.85 | 1.06 |
Fiscal Year End for Bionano Genomics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 30 | 53 | 102 | 64 | 77 |
Receivables | 6 | 8 | 9 | 9 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 19 | 20 | 23 | 26 | 32 |
Other Current Assets | 5 | 5 | 6 | 6 | 5 |
Total Current Assets | 61 | 86 | 140 | 105 | 123 |
Net Property & Equipment | 25 | 25 | 23 | 21 | 20 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 30 | 32 | 34 | 36 | 115 |
Deposits & Other Assets | 6 | 7 | 8 | 11 | 3 |
Total Assets | 129 | 158 | 214 | 182 | 271 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 19 | 29 | 70 | 0 | 0 |
Accounts Payable | 9 | 10 | 10 | 15 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 11 | 8 | 12 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 6 | 9 | 11 | 11 |
Total Current Liabilities | 37 | 59 | 100 | 40 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 4 | 4 | 4 | 4 | 4 |
Other Non-Current Liabilities | 6 | 11 | 15 | 15 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 49 | 75 | 118 | 63 | 57 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 709 | 695 | 677 | 656 | 640 |
Retained Earnings | -629 | -613 | -581 | -537 | -425 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 80 | 83 | 96 | 119 | 215 |
Total Liabilities & Shareholder's Equity | 129 | 158 | 214 | 182 | 271 |
Total Common Equity | 80 | 83 | 96 | 119 | 215 |
Shares Outstanding | 86.00 | 66.80 | 45.70 | 35.30 | 30.60 |
Book Value Per Share | 0.93 | 1.24 | 2.10 | 3.37 | 7.02 |